Search Within

Mark Blaine Geyer

Formats
  1. Meeting Abstract (43)
  2. Journal Article (35)
  3. Review (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Adult Leukemia (89)
  2. Center for Hematologic Malignancies (89)
  3. Department of Medicine (89)
  4. Hematologic Malignancies, Division of (89)
  5. Weinberg Fellows (89)
  6. Epidemiology and Biostatistics (32)

More Groups

People
  1. Jae Park (47)
  2. Martin Tallman (21)
  3. Lindsey Roeker (15)
  4. Mikhail Roshal (15)
  5. Renier Brentjens (15)
  6. Aaron Goldberg (14)

More People

Years
  1. 2025 (3)
  2. 2024 (11)
  3. 2023 (14)
  4. 2022 (6)
  5. 2021 (8)
  6. 2020 (10)

More Years

Publications
  1. Blood (36)
  2. Leukemia and Lymphoma (8)
  3. Blood Advances (5)
  4. Haematologica (3)
  5. Journal of Clinical Oncology (3)
  6. Cytotherapy (2)

More Publications

Publishers
  1. American Society of Hematology (41)
  2. Taylor & Francis Group (9)
  3. Elsevier Inc. (6)
  4. American Society of Clinical Oncology (4)
  5. Nature Publishing Group (4)
  6. American Association for Cancer Research (3)

More Publishers

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
    Journal Article

    Yang, X.; Sen, F.; Geyer, M. B.
    Leukemia Research Reports (2019)

    Fulltext@MSK | Save
  • PICALM-MLLT10 fusion commonly presents with extramedullary acute leukemia and often with a mixed phenotype (MPAL)
    Meeting Abstract

    Tashkandi, H.; Xiao, W.; Roshal, M.; Zhang, Y.; Arcila, M.; Benayed, R.; Sen, F.; Ho, C.; Baik, J.; Pichardo, J.; more...
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • PICALM-MLLT10 fusion commonly presents with extramedullary acute leukemia and often with a mixed phenotype (MPAL)
    Meeting Abstract

    Tashkandi, H.; Xiao, W.; Roshal, M.; Zhang, Y.; Arcila, M.; Benayed, R.; Sen, F.; Ho, C.; Baik, J.; Pichardo, J.; more...
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
    Journal Article

    Xiao, W.; Goldberg, A. D.; Famulare, C. A.; Devlin, S. M.; Nguyen, N. T.; Sim, S.; Kabel, C. C.; Patel, M. A.; McGovern, E. M.; Patel, A.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy
    Journal Article

    Smith, E. L.; Mailankody, S.; Staehr, M.; Wang, X.; Senechal, B.; Purdon, T. J.; Daniyan, A. F.; Geyer, M. B.; Goldberg, A. D.; Mead, E.; more...
    Cancer Immunology Research (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save
  • Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
    Journal Article

    King, A. C.; Pappacena, J. J.; Tallman, M. S.; Park, J. H.; Geyer, M. B.
    Leukemia Research (2019)

    Fulltext@MSK | Save
  • BRAF in the cross-hairs
    Review

    Geyer, M. B.; Abdel-Wahab, O.; Tallman, M. S.
    Expert Review of Hematology (2019)

    Fulltext@MSK | Save
  • First CAR to pass the road test: Tisagenlecleucel's drive to FDA approval
    Journal Article

    Geyer, M. B.
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save